Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autor: Qingchun Diao (5751701) (author)
Daljnji autori: Ruiling Jia (22654733) (author), Min Li (12799) (author), Peng Zhao (128233) (author), Fang Lu (45632) (author), Qin Zhang (58638) (author), Chunzhu Ning (22680917) (author), Juan Long (4017317) (author), Jiajia Li (184267) (author), Yan Huang (46805) (author), Yuyi Wang (462133) (author)
Izdano: 2025
Teme:
Medicine
Pharmacology
Biotechnology
Science Policy
Biological Sciences not elsewhere classified
Ivarmacitinib
moderate-to-severe atopic dermatitis
previous systemic treatments
efficacy
safety
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti